Recent developments highlight clinical progress, intellectual property expansion, and regulatory preparation milestones for Autonomix Medical's catheter-based nerve sensing and ablation platform.

• Autonomix showcased compelling proof-of-concept clinical data demonstrating rapid and durable pain relief across all disease stages of pancreatic cancer at the 2026 ASCO Gastrointestinal Cancers Symposium [N1].
• The company announced successful completion of the initial trial phase and plans for a market expansion study in pancreatic cancer pain management [N6].
• Autonomix reported successful Phase 1 trial results for pain management in pancreatic cancer and initiated a Phase 2 study [N7].
• The company plans to present its innovative neural ablation technology at EuroPCR 2025 [N1].
• Autonomix was granted a European patent for its catheter-based neuromodulation technology [N3].
• The company achieved design lock for its Apex 6 radiofrequency generator and advanced towards U.S. clinical trials for pancreatic cancer pain treatment [N1].
• Autonomix strengthened its patent portfolio with issuance of U.S. Patent No. 12,295,646 for a smart torquer device in nerve-sensing technology [N2].
• The company expanded its global intellectual property portfolio with issuance of a U.S. patent for innovative nerve-targeted treatment technologies [N3].
• Maxim Group initiated coverage of Autonomix Medical with a buy recommendation [N8].

The company has demonstrated positive initial clinical trial results for its catheter-based nerve sensing and ablation platform targeting pancreatic cancer pain, with ongoing expansion into other visceral cancers. Its technology offers a novel approach with higher sensitivity neural signal detection and integrated therapy, supported by a growing patent portfolio. Successful clinical development and regulatory approvals could enable entry into multiple large markets including oncology and cardiology. The company maintains liquidity to support near-term operations and has raised capital through equity and warrant issuances to fund development activities.

Autonomix Medical remains a development-stage company with no current revenue and significant net losses. The transition from prototype to commercial-grade device presents technical and manufacturing challenges. Clinical trials are ongoing and outcomes remain uncertain, with no guarantee of regulatory approval. The company faces Nasdaq listing compliance risks due to its stock price below minimum bid requirements, which could lead to delisting and reduced investor access. Substantial additional capital is required to fund operations and commercialization, with no assurance of availability. Market volatility and potential dilution pose further risks to shareholders.

Autonomix Medical's moat is anchored in its proprietary technology platform that combines advanced neural signal detection with therapeutic ablation in a catheter-based device. Its core innovations include a proprietary antenna array capable of capturing extremely low-amplitude neural signals and an embedded microchip for local signal processing, enabling high-fidelity, real-time nerve activity identification. The company has secured multiple patents in the U.S. and Europe protecting key aspects of its technology, including nerve-sensing and catheter-based neuromodulation for various clinical applications. This intellectual property portfolio, combined with ongoing clinical validation and regulatory development, creates barriers to entry and positions the company uniquely in the niche of nerve-targeted therapies for pain and cardiovascular indications.

• Nasdaq Listing Compliance Risk: The company is currently not in compliance with Nasdaq's minimum bid price requirement and has a compliance period until July 13, 2026, to regain compliance. Failure to do so may result in delisting, adversely affecting liquidity and investor confidence [S2].
• Capital Raising and Liquidity Risk: Autonomix estimates it requires an additional $30 to $36 million to fund operations through commercialization. There is no assurance that sufficient financing will be available on acceptable terms, which could force scaling back operations [S2].
• Clinical and Regulatory Risk: The technology remains investigational with ongoing clinical trials. There is no guarantee of favorable clinical outcomes or regulatory approvals necessary for commercialization [S2].
• Manufacturing and Commercialization Risk: Scaling from hand-assembled prototypes to commercial-grade devices involves technical and manufacturing challenges that may impact timelines and costs [S2].
• Market and Stock Volatility Risk: The company's stock price volatility and potential dilution from equity issuances may negatively impact shareholder value and market perception [S2].

• Autonomix Medical, Inc. is a development-stage medical device company pioneering a first-in-class catheter-based technology platform designed to sense and treat nervous system disorders, combining diagnostic sensing and therapeutic radiofrequency (RF) ablation [S2].
• The lead system under development targets intractable pain associated with pancreatic cancer and aims to provide minimally invasive access to deep neural structures, with potential applications in chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders [S2].
• The technology differentiates itself by detecting neural signals with greater sensitivity than commercially available systems, using a proprietary antenna array and an embedded microchip for local signal processing to minimize noise and degradation [S2].
• The product development strategy integrates diagnostic sensing to identify pathological nerve signals and therapeutic RF ablation to treat them, with preclinical models demonstrating signal detection and termination [S2].
• The company completed a first-in-human proof-of-concept study (PoC 1) in Q2 2025 for pancreatic cancer pain, showing positive clinical outcomes, and has initiated a follow-on study (PoC 2) expanding to other visceral cancers and earlier-stage pancreatic cancer patients [S2].
• The current prototype is hand-assembled and 3D-printed; efforts are ongoing to develop a commercial-grade device meeting regulatory and manufacturing standards [S2].
• Autonomix has strengthened its intellectual property portfolio with multiple U.S. and European patents issued in 2025 covering nerve-sensing technology and catheter-based neuromodulation, including patents for cardiac tissue treatment and nerve-targeted therapies [N2][N3][S2].
• The company has presented and plans to present its technology and clinical data at industry conferences such as the 2026 ASCO Gastrointestinal Cancers Symposium and EuroPCR 2025 [N1][S2].
• Financial snapshot as of March 31, 2026, shows cash and equivalents of $7.0 million, current assets of $7.58 million, current liabilities of $1.7 million, resulting in a current ratio of 4.45 and cash ratio of 4.11, indicating liquidity [S1].
• The company reported zero revenue and a net loss of $16.7 million for the fiscal year ended March 31, 2026, with basic EPS of -$2.32 per share [S1].
• Operating expenses have increased significantly, driven by research and development and general and administrative costs, reflecting ongoing clinical trials and product development [S2].
• The company is not currently in compliance with Nasdaq's minimum bid price requirement and has a compliance period until July 13, 2026, to regain compliance or face potential delisting [S2].
• Autonomix has raised capital through equity sales and warrant inducements, with net cash provided by financing activities of $10.2 million for the nine months ended December 31, 2025 [S2].
• The company estimates it will require additional financing of approximately $30 to $36 million to fund operations through commercialization of its first indication, with no assurance of availability [S2].
• Risks include clinical trial outcomes, regulatory approval, manufacturing scale-up challenges, capital raising needs, Nasdaq listing compliance, market volatility, and potential dilution to shareholders [S2].